<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915809</url>
  </required_header>
  <id_info>
    <org_study_id>GC3110B_P3</org_study_id>
    <nct_id>NCT02915809</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter Study to Compare the Immunological Efficacy and Safety of GC3110B With GCFLU Quadrivalent Inj. Administered Intramuscularly in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate immunological efficacy and safety of GC3110B versus
      GCFLU Quadrivalent Inj. among healthy adults in 18 to 60 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults 18 to 60 years of age will be randomly assigned in a 1:1 ratio to receive either
      GC3110B or GCFLU Quadrivalent Inj.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratios of Antibodies to the GC3110B or GCFLU Quadrivalent Inj.</measure>
    <time_frame>Day 0 (Pre-Vaccination) and Day 21 (Post-Vaccination)</time_frame>
    <description>Geometric mean titers of antibodies will be assessed using the hemagglutination inhibition (HI) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pre-Defined Seroconversion Before and Following Vaccination</measure>
    <time_frame>Day 0 (Pre-Vaccination) and Day 21 (Post-Vaccination)</time_frame>
    <description>Seroconversion is defined as either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1: 40 or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in post-vaccination titer 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pre-Defined Seroprotection Before and Following Vaccination</measure>
    <time_frame>Day 0 (Pre-Vaccination) and Day 21 (Post-Vaccination)</time_frame>
    <description>Antibodies will be assessed using the hemagglutination inhibition (HI) assay. Seroprotection is defined as a titer ≥1:40 at pre-vaccination and 21 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants Reporting Solicited Adverse Events Following Vaccination</measure>
    <time_frame>Day 0 to Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants Reporting Unsolicited Adverse Events Following Vaccination</measure>
    <time_frame>Day 0 to Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>GC3110B Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCFLU Quadrivalent Inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3110B vaccine</intervention_name>
    <description>0.5mL, Intramuscular</description>
    <arm_group_label>GC3110B Vaccine Group</arm_group_label>
    <other_name>GC3110B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCFLU Quadrivalent Inj. vaccine</intervention_name>
    <description>0.5mL, Intramuscular</description>
    <arm_group_label>GCFLU Quadrivalent Inj.</arm_group_label>
    <other_name>GCFLU Quadrivalent Inj.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18 to 60 years

          -  Informed consent form has been signed and dated

          -  Able to comply with the requirements of the study

        Exclusion Criteria:

          -  Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine
             components

          -  Personal history of Guillain-Barré syndrome

          -  Subjects with severe chronic disease who are considered by investigator to be
             ineligible for the study

          -  Subjects who received a vaccination within 28 days before enrollment or who are
             scheduled for another vaccination during the study

          -  Immunocompromised subjects with immunodeficiency disease or subjects receiving
             immunosuppressive or immunomodulating therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

